Description: The MHR73-11 monoclonal antibody reacts with human CD180 (RP105). This 105 kDa type I transmembrane molecule is a member of the TLR family of proteins characterized by an extracellular domain with leucine-rich repeats and a cytoplasmic domain with homology to the type I IL-1 receptor. RP105 physically associates with another molecule called MD-1 and is expressed on B, monocytes/macrophages, and dendritic cells. Histological studies show that RP105 is expressed mainly on mature B cells in mantle zones, while germinal center cells are either dull or negative. The RP105/MD-1 complex in concert with TLR4 mediates B cell recognition and signaling of LPS. MHR73-11 activates B cells, leading to increases in cell size, expression of the costimulatory molecule CD80, and DNA synthesis. Moreover, ligation of RP105 protects B cells from irradiation- or dexamethasone-induced apoptosis. Thus, RP105 is a signal transduction molecule and plays a role in regulation of B cell growth and death. A significant proportion of circulating B cells in SLE patients is RP105 negative. Loss of RP105 is associated with B cell activation and increased disease activity in SLE patients.
Applications Reported: MHR73-11 has been reported for use in flow cytometric analysis, immunoprecipitation, and immunohistochemical staining. MHR73-11 has also been reported in in vitro functional studies. (Please use Functional Grade purified MHR73-11, cat. 16-1809, in functional assays.).
Applications Tested: The MHR73-11 antibody has been tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Purity: Greater than 90%, as determined by SDS-PAGE.
Aggregation: Less than 10%, as determined by HPLC.
Filtration: 0.2 µm post-manufacturing filtered.
CD180 (RP105, Bgp95, LY64) is a type I membrane glycoprotein of Toll-like receptor (TLR) family. CD180 cytoplasmic tail is short and unlike the TLRs, it lacks the TIR domain. CD180 expression is dependent on the coexpression of its helper molecule, MD-1, and mirrors that of TLR4 on antigen-presenting cells. CD180 regulates recognition of LPS and signaling in B cells, via interacting directly with the TLR4 signaling complex, inhibiting its ability to bind microbial ligands. Ligation of CD180 by monoclonal antibodies leads to B cell activation, upregulation of CD80/CD86, and increase in cell size. CD180 consists of extracellular leucine-rich repeats (LRR) and a short cytoplasmic tail. The extracellular LRR is part of the cell surface receptor complex, RP105/MD-1. Diseases associated with CD180 dysfunction include Kawasaki Disease in children and may play a role in rheumatic disease pathology.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: CD180; CD180 antigen; Lymphocyte antigen 64; lymphocyte antigen-64, radioprotective, 105kDa; MGC126233; MGC126234; Radioprotective 105 kDa protein
Gene Aliases: CD180; LY64; Ly78; RP105
UniProt ID: (Human) Q99467
Entrez Gene ID: (Human) 4064
Molecular Function: transmembrane signal receptor